Biologics dose escalation for the treatment of inflammatory bowel disease a review of clinical effectiveness, cost-effectiveness, and guidelines
Up to one-third of inflammatory bowel disease (IBD) patients can experience that biologics become less effective and fail to maintain disease remission. In these cases, dose intensification or more frequent dosing have been considered and tried. However, the safety profile of intensified dosing and...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
CADTH
2018, August 28, 2018
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Up to one-third of inflammatory bowel disease (IBD) patients can experience that biologics become less effective and fail to maintain disease remission. In these cases, dose intensification or more frequent dosing have been considered and tried. However, the safety profile of intensified dosing and the effects on paradoxical reactions remain a subject of research. There is a need to review the effectiveness and risks of the biologics that are infused more frequently or at higher doses. To answer this question, we aim to review the literature and compare the clinical utilities and cost-effectiveness of higher or more frequent than standard dosing of biologics with standard dosing for the treatment of IBD. |
|---|---|
| Physical Description: | 1 PDF file (30 pages) illustrations |